Data Integrity, Lab Control Issues Lead to 483s for Two Manufacturers Post author:Sam Post published:February 12, 2017 Post category:Drug GMP Report The FDA issued Form 483s to two drug manufacturers for data integrity and laboratory issues. Source: Drug GMP Report You Might Also Like MHRA Includes GMP, Quality in its Top Priorities May 2, 2017 EMA Recommends Extending GMP Certificates Until End of 2021 May 5, 2020 FDA Offers Advice on Control of Nitrosamines in Drugs October 6, 2020